INTRODUCTION {#s1}
============

Physical plasma is ionized gas consisting of charged particles, radicals, reactive atoms and molecules, and ultraviolet photons. Non-thermal dielectric barrier discharge (DBD) plasma is a type of plasma that occurs at atmospheric pressure when either high voltage time-varying waveform or short duration pulses are applied to two electrodes, creating electrically safe plasma without substantial gas heating \[[@R1]--[@R3]\]. Advancements in DBD plasma system with a discharge sufficiently uniform and moderate neutral gas close to room temperature promote its medical and biological applications to living cells and tissues \[[@R2], [@R4]--[@R8]\]. In this previous study, we found that exposure to plasma at specific potentials and durations promoted soybean seed germination and sprout growth, while excess exposure inhibited growth \[[@R9]\]. This study is inspired by our previous work examining the effects of non-thermal DBD plasma on the promotion of plant growth. In the study, we decided to determine whether non-thermal DBD plasma affects growth rate in animals. To answer this question, we examined the effects on embryonic development in chickens after irradiation of fertilized eggs with non-thermal DBD plasma.

Chickens have unique embryonic development characteristics, as a result of oviparity, which are easily accessible and can be manipulated without maternal impact or external influences. Embryonic development is observable via candling and the exact embryonic age can easily be determined based on size and appearance \[[@R10]\]. Furthermore, early cell division, growth, and segregation into specific tissues occurs even in unincubated fertilized eggs \[[@R11]\]. When incubation starts, embryonic development continues, the embryo contains all organs needed to sustain life after hatching and the majority of these organs can be easily identified by the end of Hamburger-Hamilton (HH) stage 20 \[[@R10]\]. During embryonic development, a stage-dependent reaction on chemical and physical factors was found in mammals \[[@R12]\]. Unlike mammals, chicken embryos have no preimplantation stages, but resistance of chicken embryos at different stages of development to various external forces \[[@R13]\] and an age-related cellular resistance to viral infections were also found during chicken embryogenesis \[[@R14]\]. Furthermore, various cells have been shown to be highly susceptible to plasma treatment \[[@R15]--[@R17]\]. Whether chicken embryos have sensitivity to plasma treatment and exist stage-dependent reactions remain to be answered.

*In vitro* experiments with fibroblasts \[[@R18]\], endothelial cells \[[@R1]\], epithelial cells \[[@R2]\], myoblast cells \[[@R19]\], and tumor cells \[[@R20]\] have demonstrated that the effects of plasma exposure on these cell types are dose-dependent. Low intensity plasma exposure enhanced endothelial and epithelial cell proliferation \[[@R1], [@R2]\], while high doses of plasma had anti-proliferative effects on various kinds of mammalian normal cells and cancer cells and induced apoptosis \[[@R18]--[@R20]\]. Therefore, we hypothesize that non-thermal DBD plasma affects chicken embryonic development in a dose-dependent manner during the early stages of development.

When cells or tissue surfaces are exposed to non-thermal DBD plasma a variety of biologically active reactive species are generated, particularly, reactive oxygen species (ROS) \[[@R3], [@R21], [@R22]\], which are known to directly activate multiple proteins involved in the signaling pathways that increase cell function \[[@R20], [@R23], [@R24]\]. ROS levels are controlled by an inducible antioxidant system that responds to cellular stressors and is predominantly regulated by nuclear factor erythroid 2-related factor 2 (NRF2) and its repressor protein kelch like ECH associated protein 1 (KEAP1) \[[@R25], [@R26]\]. NRF2-antioxidant signaling pathway is important for the amelioration of oxidative stress \[[@R27], [@R28]\]. Oxidative stress mediated the effects of non-thermal plasma on the inhibition of mammalian normal cells deficiencies \[[@R2], [@R29]\] and the synergistic apoptosis of malignant cells \[[@R20], [@R30]\] by increasing the formation of excessive intracellular ROS. Here, we examine the effects of non-thermal DBD plasma on chicken embryonic development and explore the roles of oxidative stress via mediating ROS level and NRF2-antioxidant signaling pathway.

RESULTS {#s2}
=======

Effect of plasma on embryonic development {#s2_1}
-----------------------------------------

All embryos from stages HH 04 and HH 20 died following treatment with non-thermal DBD plasma at voltages ranging from 11.7 kV to 27.6 kV for 4 min (Figure [1](#F1){ref-type="fig"}). As compared to the control embryos (no plasma treatment; 0 kV) and positive control embryos (stage HH 04 treated with plasma at 11.7 kV for 1 min), embryos at stage HH 04 exposed to 11.7 kV, 16.4 kV, 22.0 kV, and 27.6 kV plasma for 4 min were found to die, on average, at stages embryonic day 14 (E14), E12, E9.75, and E6.125, respectively, according to the Hamburger-Hamilton stages (Table [1](#T1){ref-type="table"}, Figure [1A--1D](#F1){ref-type="fig"}) \[[@R10]\]. As compared to the control and positive control embryos (stage HH 20 treated with plasma at 11.7 kV for 1 min), embryos at stage HH 20 exposed to 11.7 kV, 16.4 kV, 22.0 kV, and 27.6 kV plasma for 4 min were found to die, on average, at stages E17, E16, E15, and E13, respectively (Table [1](#T1){ref-type="table"}, Figure [1E--1H](#F1){ref-type="fig"}). These results show that exposure to plasma at higher voltages for 4 min increases the rate embryo death, and embryos at stage HH 20 survive longer than those at stage HH 04 which indicates that the stage HH 20 embryos are more resistant to the lethal effects of the plasma.

![Effect of plasma on chicken embryonic development\
Embryos at stage HH 04 were treated at voltages of (**A**) 11.7 kV, (**B**) 16.4 kV, (**C**) 22.0 kV, (**D**) 27.6 kV and HH 20 were treated at voltages of (**E**) 11.7 kV, (**F**) 16.4 kV, (**G**) 22.0 kV, (**H**) 27.6 kV for 4 min, and returned to the incubator. Fertilized eggs not treated with plasma were used as the control group (0 kV). Embryos at stage HH 04 or HH 20 treated with plasma at 11.7 kV for 1 min were correspondingly used as the positive control. The death day was estimated according to the Hamburger-Hamilton stages. E represents the embryonic day.](oncotarget-08-85642-g001){#F1}

###### Effect of plasma on chicken dead embryonic stage and number

  Group                  0 kV   Embryos at stage HH 04   Embryos at stage HH 20   Positive control                                          
  ---------------------- ------ ------------------------ ------------------------ ------------------ ---- ---- ---- ----- ----- ----- ----- -----
  Dead embryonic stage   ---    E14                      E12                      E10                E9   E7   E6   E17   E16   E15   E13   ---
  Dead number            0      8                        8                        6                  2    1    7    8     8     8     8     0

Embryos at stage HH 04 or HH 20 were treated at voltages of 11.7 kV to 27.6 kV for 4 min, and returned to the incubator. Fertilized eggs not treated with plasma were used as the control group (0 kV). Embryos at stage HH 04 or HH 20 treated with plasma at 11.7 kV for 1 min were correspondingly used as the positive control. Eight fertilized eggs were used in each group. The number of dead embryos was recorded, and death day was estimated according to the Hamburger-Hamilton stages. E represents the embryonic day.

Effect of plasma on ROS levels {#s2_2}
------------------------------

ROS levels in the skeletal muscle tissues of the chicken embryos at stage HH 20 exposed to plasma for 4 min increased with increases in applied in electric potential as compared to the control and positive control groups. Exposure to 27.6 kV increased ROS levels by 1.40-fold (*p \<* 0.001) over the control group (Figure [2A](#F2){ref-type="fig"}). Expression of nicotinamide adenine dinucleotide phosphate oxidase 4 (*NOX4*) mRNA expression, an enzyme that produces ROS, increased 1.34-fold (*p \<* 0.001) following exposure to plasma at 27.6 kV for 4 min (Figure [2B](#F2){ref-type="fig"}). However, the mRNA expression level of *NRF2*, an activator of genes that encode enzymes and proteins involved in detoxification and antioxidant effects, decreased 0.60-fold (*p \<* 0.001; Figure [2B](#F2){ref-type="fig"}) and protein levels decreased 0.38-fold (*p \<* 0.001) after plasma treatment at 27.6 kV for 4 min (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). Furthermore, the expression of *KEAP1*, which targets NRF2 for ubiquitination and subsequent proteolysis, increased 1.00-fold (*p \<* 0.001) in mRNA expression (Figure [2B](#F2){ref-type="fig"}) and 0.82-fold (*p \<* 0.001) in protein expression following plasma treatment at 27.6 kV as compared with the control group (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}).

![Effect of plasma on ROS levels\
(**A**) ROS levels, (**B**) Relative mRNA expression of *NOX4*, *NRF2*, and *KEAP1* in the skeletal muscle tissues of the chicken embryos at stage HH 20 exposed at different plasma potential for 4 min. Fertilized eggs not treated with plasma were used as the control group (0 kV). Embryos at stage HH 20 treated with plasma at 11.7 kV for 1 min were used as the positive control. ROS level in the skeletal muscle was expressed as nmole DCF/mg protein. mRNA expression was determined by RT-PCR analysis, and normalized to the *β-actin* mRNA level. Values are expressed as the mean ± standard error (*n* = 3). \**p \<* 0.05 versus control; \*\**p \<* 0.01 versus control, according to one-way ANOVA and LSD test.](oncotarget-08-85642-g002){#F2}

Antioxidant enzyme activity {#s2_3}
---------------------------

The activities of the antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) decreased following exposure to plasma for 4 min in the skeletal muscle tissues of the dead embryos. However, malondialdehyde (MDA) levels increased in a dose-dependent manner. Treatments with 27.6 kV plasma elicited the greatest changes across the potential range (11.7 to 27.6 kV), resulting in 0.51- (*p \<* 0.001), 0.82- (*p \<* 0.001), and 0.66-fold (*p \<* 0.001) decreases in SOD, CAT, and GPx, respectively, and a 1.29-fold (*p \<* 0.001) increase in MDA (Figure [3A](#F3){ref-type="fig"}, [3B](#F3){ref-type="fig"}, [3C](#F3){ref-type="fig"}, and [3D](#F3){ref-type="fig"}). *SOD*, *CAT*, and *GPx* mRNA expression levels decreased following 4 min plasma exposure across the potential range (11.7 to 27.6 kV), in a dose-dependent manner, with the greatest decreases in *SOD*, *CAT*, and *GPx* of 0.47- (*p \<* 0.001), 0.67- (*p \<* 0.001), and 0.65-fold (*p \<* 0.001) in the group treated with 27.6 kV, respectively (Figure [3E](#F3){ref-type="fig"}). The 27.6 kV plasma treatment had the largest inhibitory effect on peroxiredoxin (*PRDX*)*-*family gene expression in the skeletal muscle tissue of the dead embryos, resulting in decreases of 0.49- (*p \<* 0.001), 0.80- (*p \<* 0.001), 0.39- (*p \<* 0.001), and 0.64-fold (*p \<* 0.001) in *PRDX1*, *PRDX3*, *PRDX4*, and *PRDX6*, respectively (Figure [3F](#F3){ref-type="fig"}). PRDX3 protein expression decreased 0.68-fold (*p \<* 0.001) after treatment at 27.6 kV for 4 min (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}).

![Effect of plasma on antioxidant enzyme\
Activities of (**A**) SOD, (**B**) CAT, (**C**) GPx, and (**D**) MDA, and relative mRNA expression of (**E**) *SOD*, *CAT*, and *GPx*, and (**F**) *PRDX1*, *PRDX3*, *PRDX4*, and *PRDX6* in the skeletal muscle tissues of the chicken embryos at stage HH 20 exposed at different plasma potential for 4 min. Control and positive control were as described before. mRNA expression was determined by RT-PCR analysis, and normalized to the *β-actin* mRNA level. Values are expressed as the mean ± standard error (*n* = 3). \**p \<* 0.05 versus control; \*\**p \<* 0.01 versus control, according to one-way ANOVA and LSD test.](oncotarget-08-85642-g003){#F3}

Levels of adenosine triphosphate (ATP) and growth-related factors {#s2_4}
-----------------------------------------------------------------

ATP levels in the skeletal muscle tissue of the dead embryos, for each of the different electrical potentials examined, decreased following exposure to plasma for 4 min and increases in the electric potential increased the inhibitory effects of the plasma on these levels. At 27.6 kV, exposure to plasma decreased the ATP concentration by 0.54-fold (*p \<* 0.001; Figure [4A](#F4){ref-type="fig"}). *ATP* synthase mRNA expression levels in the skeletal muscle also correlated with plasma exposure potential. The greatest inhibitory effects were found at 27.6 kV, where 0.82-fold (*p \<* 0.001) reductions in *ATP5A1*, 0.61-fold (*p \<* 0.001) in *ATP5B*, 0.69-fold (*p \<* 0.001) in *ATP5C1*, 0.75-fold (*p \<* 0.001) in *ATP5F1*, 0.61-fold (*p \<* 0.001) in *ATP5G1*, 0.54-fold (*p \<* 0.001) in *ATP5G3*, 0.53-fold (*p \<* 0.001) in *ATP5H*, 0.67-fold (*p \<* 0.001) in *ATP5I*, 0.52-fold (*p \<* 0.001) in *ATP5J*, 0.73-fold (*p \<* 0.001) in *ATP5J2*, 0.69-fold (*p \<* 0.001) in *ATP5L*, and 0.60-fold (*p \<* 0.001) in *ATP5S* synthase mRNA expression were observed (Figure [4B](#F4){ref-type="fig"}). Similar decreases in mRNA expression in growth hormone (*GH*), growth hormone receptor (*GHR*), insulin-like growth factor 1 (*IGF1*), insulin-like growth factor 1 receptor (*IGF1R*), POU class 1 homeobox 1 (*POU1F1*), and mammalian target of rapamycin (*mTOR*) were found. At 27.6 kV, *GH*, *GHR*, *IGF1*, *IGF1R*, *POU1F1*, and *mTOR* expression decreased 0.79- (*p \<* 0.001), 0.86- (*p \<* 0.001), 0.70- (*p \<* 0.001), 0.76- (*p \<* 0.001), 0.56- (*p \<* 0.001), and 0.74-fold (*p \<* 0.001), respectively (Figure [4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). However, exposure to plasma incrementally increased the mRNA expression levels of insulin-like growth factor binding protein 2 (*IGFBP2*) and AMP-activated protein kinase (*AMPK*). At 27.6 kV, increases of 1.95- (*p \<* 0.001), 1.15- (*p \<* 0.001), 0.74- (*p \<* 0.001), and 0.68-fold (*p \<* 0.001) in the expression of *IGFBP2*, *AMPKα2*, *AMPKβ2*, and *AMPKγ3*, respectively, were observed (Figure [4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}).

![Effect of plasma on ATP and growth-related factors\
(**A**) ATP levels, relative mRNA expression of (**B**) *ATP5A1*, *ATP5B*, *ATP5C1*, *ATP5F1*, *ATP5G1*, *ATP5G3*, *ATP5H*, *ATP5I*, *ATP5J*, *ATP5J2*, *ATP5L*, and *ATP5S*, (**C**) *GH*, *GHR*, *IGF1*, *IGF1R*, *IGFBP2*, and *POU1F1*, and (**D**) *AMPKα2*, *AMPKβ2*, *AMPKγ3*, and *mTOR* in the skeletal muscle tissues of the chicken embryos at stage HH 20 exposed at different plasma potential for 4 min. Control and positive control were as described before. mRNA expression was determined by RT-PCR analysis, and normalized to the *β-actin* mRNA level. Values are expressed as the mean ± standard error (*n* = 3). \**p \<* 0.05 versus control; \*\**p \<* 0.01 versus control, according to one-way ANOVA and LSD test.](oncotarget-08-85642-g004){#F4}

Plasma exposure also had significant effects on protein levels in the skeletal muscle tissue of the dead embryos. Exposure to plasma at 27.6 kV for 4 min significantly decreased the expressions of ATP5A and GHR, and reduced the phosphorylation level of mTOR in the dead embryos by 0.60- (*p* \< 0.001), 0.85- (*p* \< 0.001), and 0.71-fold (*p* \< 0.001), respectively (Figure [5C](#F5){ref-type="fig"} and [5E](#F5){ref-type="fig"}), compared to that in control embryos. However, this same exposure to plasma increased IGFBP2 expression and the level of phosphorylation of AMPK by 3.58- (*p* \< 0.001) and 1.19-fold (*p* \< 0.001), respectively (Figure [5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}).

![Effect of plasma on protein expression\
(**A**) Immunoblots of protein bands. Relative protein levels of (**B**) NRF2, KEAP1, and PRDX3, (**C**) ATP5A, GHR, and IGFBP2, (**D**) p-AMPK/AMPK, and (**E**) p-mTOR/mTOR. Protein was extracted from the skeletal muscle tissues of the chicken embryos at stage HH 20 exposed at 27.6 kV for 4 min. Control and positive control were as described before. The densitometric values of the NRF2, KEAP1, PRDX3, ATP5A, GHR, and IGFBP2 signals were normalized to the relevant β-actin signal. The densitometric value of each p-AMPK, AMPK, p-mTOR, and mTOR band was normalized to the β-actin signal in the same sample before calculating the p-AMPK/AMPK and p-mTOR/mTOR ratios. Values are expressed as the mean ± standard error (*n* = 3). \**p \<* 0.05 versus control; \*\**p \<* 0.01 versus control, according to one-way ANOVA and LSD test.](oncotarget-08-85642-g005){#F5}

DISCUSSION {#s3}
==========

In a previous study, we showed exposure to non-thermal DBD plasma at certain electrical potentials and for specific durations can promote soybean sprout growth \[[@R9]\]. Therefore, this study explored the effects of plasma on chicken embryonic development. We chose to expose the embryos for 4 min to plasma, at different electrical potentials, in order to determine the effects on embryonic development. We examined the effects of non-thermal DBD plasma exposure on embryonic development by irradiating fertilized eggs at the HH 04 and HH 20 stages of development. Chicken embryos at stage HH 04 or HH 20 treated with plasma at 11.7 kV for 1 min were used as the positive control because this exposure condition improved chicken embryo growth. Our results show that plasma exposure at 11.7 kV for 1 min promoted chicken embryonic development, but 4 min of exposure resulted in dose-dependent embryonic death; at higher potentials (up to 27.6 kV) the rate of death increased. These results are consistent with previous findings that showed low-doses of plasma enhance cell proliferation, while high-doses induce cell death \[[@R1], [@R2], [@R18]--[@R20]\]. Furthermore, longer durations of plasma exposure increased apoptotic cell number in immune cell lines \[[@R15]\], decreased cell viability and proliferation \[[@R31]\], and caused endothelial cell toxicity \[[@R1]\]. These findings led us to conclude that 4 min exposure would be lethal to the chicken embryos.

Some early embryonic development takes place in fertilized eggs before incubation \[[@R11]\]. Once incubation begins, a pointed, thickened layer of cells becomes visible at the caudal end of the embryo. Embryos at stage HH 20 have all of the organs needed for growth \[[@R10]\]. Our results show that embryos at stage HH 20 have a longer survival time following exposure to plasma than the earlier stage HH 04 embryos. This is likely due to the establishment of a complete embryo structure by the end of stage HH 20, which would result in increased resistance to the harmful external factors. In addition, this is supported by the facts that embryos have stage-dependent resistances to various external factors during embryogenesis \[[@R12]--[@R14]\]. But we are not sure whether mammals have stage-dependent resistance to non-thermal DBD plasma because the embryonic development of mammals is different from that of chickens.

Non-thermal DBD plasma treatment induces oxidative stress from the diffusion of plasma-generated ROS, or from stimulation of the cell's own ROS generating mechanisms \[[@R32]\], which results in decreased cell proliferation and differentiation \[[@R31]\], even cell death \[[@R29], [@R30], [@R32]\]. Our results show 4 min plasma exposure generated excessive ROS and increased MDA activity in dead embryos, which were mediated by decreasing cellular antioxidant activity and metabolic viability \[[@R20], [@R33]\], and correlated with elevated *NOX4* mRNA expression, which catalyzes the reduction of molecular oxygen to generate ROS \[[@R34]--[@R36]\]. NRF2 directly affects ROS levels by regulating the antioxidant defense systems through the induction of catabolism in SOD, CAT, GPx, and PRDX \[[@R26], [@R28], [@R37]\]. KEAP1 targets NRF2 for proteasomal degradation \[[@R27], [@R38], [@R39]\]. We found plasma increased KEAP1 level and decreased NRF2 level, activity and mRNA level of SOD, CAT, and GPx, and PRDX mRNA and protein in the dead embryos. These facts indicated oxidative stress was involved in the plasma-induced chicken embryonic death, resulting from the excessive accumulation of ROS and deficiency of antioxidant defense system that was suppressed by the disruption of NRF2-antioxidant signaling pathway.

ATP synthase is an important enzyme that provides energy for the cell via the production of ATP. Plasma treatment causes a decrease in mitochondrial transmembrane potential and subsequent mitochondrial enzymatic dysfunction and morphological alterations \[[@R40], [@R41]\] as a result of intracellular ROS accumulation that induces mitochondrial DNA oxidative damage, and disrupts DNA transcription and ATP production in the mitochondria \[[@R42]\]. Our results show exposure to plasma decreased ATP concentration, *ATP* synthase subunit mRNA level and ATP5A protein expression in the embryo skeletal muscle tissue. The results indicate that sustained plasma exposure inhibits ATP production, thus, negatively impacting cell proliferation and embryonic development. It is important to mention that ATP level in this study of plasma on chicken embryos was in contrast to other's study that plasma-induced secretion of ATP and fluctuations in ATP level as a representative secreted damage-associated molecular patterns in carcinoma cells \[[@R32]\]. In addition, our results that plasma increased *AMPK* mRNA level and AMPK phosphorylation, decreased *mTOR* mRNA level and mTOR phosphorylation in dead embryo skeletal muscle tissue can be explained by the fact that ATP depletion activates AMPK, which in turn phosphorylates and activates the tuberous sclerosis complex, leading to the inhibition of mTOR \[[@R43]\].

We found that growth-related genes are involved in the plasma-treated chicken embryonic development. The results show plasma decreased mRNA level of *GH*, *GHR*, *IGF1*, *IGF1R*, and *POU1F1*, and increased *IGFBP2* mRNA and protein expression in the dead embryos. GH stimulates muscle and bone growth, and cell reproduction in animals \[[@R44]\] through its interaction with GHR \[[@R45]\]. GH-GHR binding stimulates the synthesis and release of IGF-1 \[[@R46]\], which is essential for embryonic development and post-hatching growth \[[@R47]\]. IGFBP2, the major IGFBP in chicken, has a specific, high-affinity for IGF1 and blocks IGF1 access to IGF1R, thereby inducing antiproliferative effects \[[@R47]\]. POU1F1 has a high affinity DNA binding domain which targets the genes that encode GH \[[@R48]\]. Our results indicate plasma exposure slows the signaling cascade involving GH and IGF-1, which induces the inhibition of cell reproduction and growth during embryonic development. In addition, GH has been shown to decrease the rate of mitochondrial ROS generation \[[@R49]\], and IGF-1 expression reduces ROS production from metabolism \[[@R50]\]. These previous findings may explain how the low mRNA level of *GH* and *IGF1* in the plasma-treated embryos contributed to increased intracellular ROS levels, and thereby, inhibiting embryonic development.

In conclusion, the duration and intensity of plasma exposure must be optimized for use in animal systems. Our results demonstrate the potential for non-thermal DBD plasma treatment in the promotion of growth in chicken, which we believe to be worthy of further exploration.

MATERIALS AND METHODS {#s4}
=====================

Ethics {#s4_1}
------

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH Pub. No. 85--23, revised 1996). Animal handling protocols were approved by the Animal Care and Use Committee of Jeju National University (approval number: 2016--0022).

Plasma treatment and fertilized egg incubation {#s4_2}
----------------------------------------------

Figure [6A](#F6){ref-type="fig"} shows the dielectric barrier discharge plasma reactor, which operates at atmospheric pressure, used in this study. The reactor consists of two 100 mm wide disk-shaped electrodes and a 5 mm thick glass dielectric barrier. The upper electrode has 16 needles (thickness: 1 mm; length: 2.5 mm) that are evenly distributed on its inner surface, pointing downward towards the lower electrode. The distance between the needle tip and the ceramic dielectric barrier placed on the lower electrode is 30 mm. The plasma reactor was energized by high voltage alternating current (operating frequency: 60 Hz), and pure argon was fed to the reactor at a flow rate of 2 l/min. The voltage was measured using a digital oscilloscope (Tektronix, Beaverton, OR, USA) and a 1000:1 high voltage probe (P6015, Tektronix). The discharge power was determined using a voltage-charge Lissajous plot, and the charge was recorded by measuring the voltage across the 1.0 µF capacitor connected to the plasma reactor in series. As shown in Figure [6B](#F6){ref-type="fig"}, the discharge power increases exponentially from 0.05 to 14.28 W, as the voltage is changed from 11.7 to 27.6 kV rms.

![Non-thermal DBD plasma treatment\
(**A**) Plasma reactor schematic. (**B**) Voltage and discharge power applied in plasma treatment. (**C**) Fertilized egg schematic.](oncotarget-08-85642-g006){#F6}

Fresh fertilized eggs (approximately 50 g each) were obtained from farm-raised Hyline Brown hens (Jeju National University, Jeju, Republic of Korea). The hens were artificially inseminated twice a week with semen from Korean native cocks. The egg shells were wiped with 70% ethanol and put into an incubator with 45% to 65% relative humidity at 37.5°C and rotated 90 degrees every 2 hours. The embryos used in the plasma treatments were at either stage HH 04 or HH 20 in development. The embryos were placed in the plasma reactor with the blastoderm near the voltage probe (Figure [6C](#F6){ref-type="fig"}) and treated at different potentials for 4 min at room temperature, and returned to the incubator. Fertilized eggs not treated with plasma were used as the control group (0 kV). Embryos at stage HH 04 or HH 20 treated with plasma at 11.7 kV for 1 min were correspondingly used as the positive control group. Candling was performed on days 5, 12, and 19 during incubation. All dead embryos were removed from the shell by tearing the allantois and amnion with forceps. Eight fertilized eggs were used in each group. The number of dead embryos was recorded, and death day was estimated according to Hamburger-Hamilton stages \[[@R10]\].

ROS, antioxidant enzyme, and ATP analyses {#s4_3}
-----------------------------------------

Skeletal muscle homogenates were prepared out in 1 ml ice-cold 0.1% sodium dodecyl sulfate (SDS; dissolved in PBS, 0.05 mol/l, pH 7.4) using a homogenizer, followed by centrifugation (12,000 × *g*) for 10 min at 4°C. Supernatant protein concentrations were analyzed using a Bicinchoninic Acid Protein Assay Kit (Sigma-Aldrich, St. Louis, MO, USA) and the concentrations were normalized using PBS. ROS levels were determined using the OxiSelect *In Vitro* ROS/RNS Assay Kit (Cell Biolabs, Inc., San Diego, CA, USA). The assay employs a proprietary quenched fluorogenic probe 2′,7′-dichlorodihydrofluorescein DiOxyQ (DCFH-DiOxyQ), which is a specific ROS/RNS probe that is based on similar chemistry to 2′,7′-dichlorodihydrofluorescein diacetate. The DCFH-DiOxyQ probe is first primed with a quench removal reagent, and subsequently stabilized in the highly reactive DCFH form, which is rapidly oxidized to the highly fluorescent 2′,7′-dichlorodihydrofluorescein (DCF) by ROS/RNS. The amount of DCF in the sample is determined based on the relative fluorescence units obtained using a DCF standard curve and the fluorescence intensity of DCF is proportional to the total ROS/RNS level within the sample, using a GloMax Discover Multimode Detection System fluorescence plate reader (Promega, Madison, WI, USA) at 480 nm excitation/530 nm emission.

The homogenate supernatant was assayed for SOD, CAT, GPx, MDA, and ATP concentrations using kits from Invitrogen and Sigma-Aldrich, according to the manufacturer's instructions. The optical density of SOD, CAT, GPx, and MDA were detected using the GloMax Discover Multimode Detection System (Promega). The relative light unit values of ATP level were measured using a luminometer (Sirius L Tube Luminometer, Titertek Berthold, Germany). SOD activity was expressed as U/mg protein, where one unit was defined as the amount of enzyme that reduces 1.0 µmole of superoxide to molecular oxygen and hydrogen peroxide per min at 25°C. CAT activity was expressed as U/mg protein, wher U was defined as the amount of enzyme that decomposes 1.0 µmole of hydrogen peroxide to oxygen and water per min at 25°C. GPx activity was expressed as mU/mg protein, where mU was defined as the amount of enzyme that will cause the oxidation of 1.0 nmole of NADPH to NADP^+^ under the assay kit condition per min at 25 °C. MDA and ATP levels were expressed as nmole/mg protein in muscle tissue.

RT-PCR analysis {#s4_4}
---------------

Total RNA was extracted and purified from chicken embryo skeletal muscle tissue using the TRIzol Reagent (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), following the manufacturer's instructions. RT-PCR analysis was performed using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen), Prime Taq Premix (2×) (GENETBIO, Yuseong-gu, Daejeon, South Korea), EvaGreen Dye (Biotium, Hayward, CA, USA). First-strand cDNA synthesis was performed using 1 μl total RNA (1 μg/μl), following the manufacturer's protocol. RT-PCR was performed using a StepOne Real-time PCR system (Applied Biosystems, Thermo Fisher Scientific). The RT-PCR conditions included initial denaturation at 95°C for 10 min, followed by denaturation at 95°C for 15 s and annealing for 1 min at the temperatures shown in Table [2](#T2){ref-type="table"} for 40 cycles, and melting curves were derived at temperatures of 95°C for 15 s, 60°C for 1 min, and increased to 95°C for 15 s by 0.3°C. Primer sequences for RT-PCR ware shown in Table [2](#T2){ref-type="table"}.

###### Primer sequences for the RT-PCR

  Gene                         Sequence number   Sequence position   Product length (bp)   Annealing Temperature (°C)   Sequence (5′ to 3′)
  ---------------------------- ----------------- ------------------- --------------------- ---------------------------- ----------------------------
  β-actin                      NM_205518.1       625--818            194                   57                           F: GTGCGTGACATCAAGGAGAAGC
  R: CCACAGGACTCCATACCCAAGA                                                                                             
  NOX4                         NM_001101829.1    28--157             130                   57                           F: CGAGGATCTCAGAAGGTTGC
  R: GAGCATTCACCAGATGAGCA                                                                                               
  NRF2                         NM_205117.1       484--619            136                   57                           F: AAAACGCTGAACCACCAATC
  R: GCTGGAGAAGCCTCATTGTC                                                                                               
  KEAP1                        KU321503.1        1227--1485          259                   57                           F: GTATCACAGCAGCGTGGAGA
  R: GGCGTAGATGCAGTTGTTGA                                                                                               
  SOD                          NM_205064.1       106--278            173                   55                           F: ATTACCGGCTTGTCTGATGG
  R: CCTCCCTTTGCAGTCACATT                                                                                               
  CAT                          NM_001031215.2    1067--1276          210                   55                           F: CTCATTCCAGTGGGCAAGAT
  R: GTAGGGGCAATTCACAGGAA                                                                                               
  GPx                          NM_001277853.2    353--474            122                   55                           F: ATGTTCGAGAAGTGCGAGGT
  R: ATGATGTACTGCGGGTTGGT                                                                                               
  PRDX1                        NM_001271932.1    358--545            188                   56                           F: ACAAGGTGGTTTGGGCACTA
  R: TCTCATCAACAGAACGGCCA                                                                                               
  PRDX3                        XM_426543.5       414--551            138                   56                           F: TTTCACCTTTGTGTGCCCCA
  R: TTGCGCGGGGTATTTATCCA                                                                                               
  PRDX4                        XM_001233999.3    595--733            139                   56                           F: TGCACTTAGGGGCCTTTTCA
  R: TTCTCCATGCTTGTCCGTGT                                                                                               
  PRDX6                        NM_001039329.2    189--340            152                   58                           F: TGAGTTCAGCAAACGCAACG
  R: GCTCTCGGTCCTTATCAGCG                                                                                               
  ATP5A1                       NM_204286.1       1207--1364          158                   57                           F: GGTATCCGTCCAGCCATCAA
  R: GCATCCAAATCAGACCCAAACT                                                                                             
  ATP5B                        NM_001031391.2    482--637            156                   57                           F: GCCCCATCACAACGAAACAG
  R: CGCCTCCAAACAAACCAATC                                                                                               
  ATP5C1                       NM_001278096.1    272--411            140                   57                           F: ATTAAGGCACCCGAGGACAA
  R: ACTTCCTTCCCTGCATTGGA                                                                                               
  ATP5F1                       XM_417993.4       437--644            208                   57                           F: CATTGGAGACTGCCATTGAGG
  R: TGATCTTGCTCTTTCTGACGCTT                                                                                            
  ATP5G1                       XM_001233602.3    287--536            250                   57                           F: CAGGAGCAGGTATTGGGACA
  R: TTGTCAGTCTGGAACGCTCT                                                                                               
  ATP5G3                       NM_001277855.1    141--288            148                   57                           F: CCAAAACGCTGTCTCCCAAC
  R: ACCGAAGACCGTTCCAATACC                                                                                              
  ATP5H                        XM_001232598.3    332--551            220                   57                           F: CTGAAGGTCCCTGAACCAGT
  R: ACTTCTCCCTGTCCAGTCTG                                                                                               
  ATP5I                        NM_001097534.2    74--240             167                   57                           F: TCTCGCCCCTCATCAAGTTC
  R: TGCCAGTTCCTTTGCAATCC                                                                                               
  ATP5J                        XM_004938370.1    58--197             140                   58                           F: CACTTGCGGAGAAACATCGGT
  R: CCTACATCAACAGGTCCTCCAGC                                                                                            
  ATP5J2                       NM_001257200.1    170--263            94                    57                           F: GCCTCGGTGGTATCAGTATGGT
  R: TACTTCCTGCGGCGGTCAT                                                                                                
  ATP5L                        XM_015298211      250--377            128                   57                           F: CCATGGTCAGGAGCTTTCAG
  R: GCCTCGTTTGCCTATGATCTC                                                                                              
  ATP5S                        NM_001277562.1    46--279             234                   57                           F: TCCCCTTCCCCTTTCTTTCC
  R: CATAGCCTTGATAGCGCACC                                                                                               
  GH                           NM_204359.2       104--284            181                   57                           F: TGTTTGCCAACGCTGTGCT
  R: TTCTGCTGGGCGTCATCCT                                                                                                
  GHR                          NM_001001293.1    1070--1299          230                   57                           F: GTCACACAGTTGCTTGGGAG
  R: TATGCGGCTGTTGGGTATCT                                                                                               
  IGF1                         NM_001004384.2    188--316            129                   58                           F: AGTTCGTATGTGGAGACAGAGGC
  R: CCAGCCTCCTCAGGTCACAAC                                                                                              
  IGF1R                        NM_205032.1       2961--3114          154                   57                           F: TTGTGCTCCCCATTGCTTTC
  R: GGAACGTACACATCCGAAGC                                                                                               
  IGFBP2                       NM_205359.1       582--793            212                   57                           F: TCACAACCACGAGGACTCAAAG
  R: GCTGCCCATTCACCGACAT                                                                                                
  POU1F1                       NM_204319.1       560--754            195                   57                           F: ATGTTGGCGAAGCACTGGC
  R: GCTTCCTCTTCCGCTCATTCA                                                                                              
  AMPKα2                       NM_001039605.1    726--943            218                   57                           F: GGAGGCGTGTTTTACATCCC
  R: AACTTCTCACAGACCTCCCG                                                                                               
  AMPKβ2                       NM_001044662.1    435--661            227                   57                           F: CCAGTGTTTTCAGCTCCCAC
  R: GAGGTCCAGGATAGCGACAA                                                                                               
  AMPKγ3                       NM_001031258.2    183--320            138                   57                           F: GCTGGAACCCGACAACAATT
  R: GCCTTCTTGATCTCCAGGGT                                                                                               
  mTOR                         XM_417614.4       119--309            191                   57                           F: TGAAGGGGTCAAGGCAATCC
  R: GGCGAGCAGTGGTTGTGGAT                                                                                               

NOX4, nicotinamide adenine dinucleotide phosphate oxidase 4; NRF2, nuclear factor erythroid 2-related factor 2; KEAP1, kelch like ECH associated protein 1; SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase; PRDX, peroxiredoxin; ATP5A1, ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1; ATP5B, ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide; ATP5C1, ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1; ATP5F1, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1; ATP5G1, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1; ATP5G3, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C3; ATP5H, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit D; ATP5I, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit E; ATP5J, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6; ATP5J2, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F2; ATP5L, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G; ATP5S, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit S; GH, growth hormone; GHR, growth hormone receptor; IGF1, insulin-like growth factor 1; IGF1R, insulin-like growth factor 1 receptor; IGFBP2, insulin-like growth factor binding protein 2; POU1F1, POU class 1 homeobox 1; AMPKα2, AMP-activated protein kinase catalytic subunit alpha 2; AMPKβ2, AMP-activated protein kinase non-catalytic subunit beta 2; AMPKγ3, AMP-activated protein kinase non-catalytic subunit gamma 3; mTOR, mammalian target of rapamycin.

The cycle threshold values for each sample were determined using triplicate measurements. Equivalent dilutions were calculated using a standard curve and normalized to the housekeeping gene (β*-actin*). Reaction product sequences were confirmed by direct nucleotide sequencing using an ABI PRISM 7700 Sequence Detector (Applied Biosystems). Relative expression levels were calculated using the 2^-ΔΔCT^ method.

Western blotting {#s4_5}
----------------

For extraction of total protein, 0.3 g chicken skeletal muscle was cut into small pieces and resuspended in lysis buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, and 1 mg/l chymostatin) at 4 °C for 30 min prior to centrifugation for 10 min at 11,000 × *g*. The protein concentrations were determined using a Bicinchoninic Acid Protein Assay Kit (Sigma-Aldrich, St. Louis, MO, USA) using bovine serum albumin (BSA) as a standard protein. Proteins were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes by wet electrophoretic transfer (Bio-Rad, Hercules, California, USA). After blocking in PBS-Tween containing 5% dried skimmed milk or 3% BSA for 2 h at room temperature, membranes were incubated with primary detection antibodies raised against NRF2 (mouse, 1:200; Santa Cruz Biotechnology, Dallas, Texas, USA), KEAP1 (mouse, 1:200; Santa Cruz Biotechnology), PRDX3 (mouse, 1:200; Santa Cruz Biotechnology), ATP5A (rabbit, 1:250; Abcam, Cambridge, UK), GHR (rabbit, 1:500; Bioss, Woburn, MA, USA), IGFBP2 (rabbit, 1:500; Bioss), phosphorylated AMPK (Thr172, p-AMPK; rabbit, 1:1,000; Cell Signaling Technology, Beverly, MA, USA), AMPK (rabbit, 1:1,000; Cell Signaling Technology), phosphorylated mTOR (Ser2448, p-mTOR; rabbit, 1:1,000; Cell Signaling Technology), mTOR (rabbit, 1:1,000; Cell Signaling Technology), and β-actin (rabbit, 1:1,000; Bioss) at 4°C overnight. After incubation with goat anti-rabbit immunoglobulin G coupled to horseradish peroxidase (1:5,000; Abcam) or goat anti-mouse secondary antibody (1:5,000; Abcam) for 2 h at room temperature, proteins were visualized by enhanced chemiluminescence (SuperSignal West Pico; Thermo Fisher Scientific). Band intensities were quantified using Quantity One software (Bio-Rad). The densitometric values of the NRF2, KEAP1, PRDX3, ATP5A, GHR, and IGFBP2 signals were normalized to the relevant β-actin signal. The densitometric value of each p-AMPK, AMPK, p-mTOR, and mTOR band was normalized to the β-actin signal in the same sample before calculating the p-AMPK/AMPK and p-mTOR/mTOR ratios.

Statistical analysis {#s4_6}
--------------------

All experiments were performed in triplicate. Values are expressed as the mean ± standard error. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS version 16.0; SPSS, Chicago, IL, USA). Data were analyzed by one-way ANOVA and Fisher's least significant difference (LSD) test to determine treatment differences.
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ATP

:   adenosine triphosphate

AMPK

:   AMP-activated protein kinase

BSA

:   bovine serum albumin

CAT

:   catalase

DBD

:   dielectric barrier discharge

GPx

:   glutathione peroxidase

GH

:   growth hormone

GHR

:   growth hormone receptor

H~2~O~2~

:   hydrogen peroxide

IGF1

:   insulin-like growth factor 1

IGF1R

:   insulin-like growth factor 1 receptor

IGFBP2

:   insulin-like growth factor binding protein 2

KEAP1

:   kelch like ECH associated protein 1

LSD

:   least significant difference

MDA

:   malondialdehyde

mTOR

:   mammalian target of rapamycin

NOX4

:   nicotinamide adenine dinucleotide phosphate oxidase 4

NRF2

:   nuclear factor erythroid 2-related factor 2

POU1F1

:   POU class 1 homeobox 1

PRDX

:   peroxiredoxins

ROS

:   reactive oxygen species

SOD

:   superoxide dismutase

SDS

:   sodium dodecyl sulfate
